Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description HIDRA04 is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully
Theodora Kanni, Vassiliki Tzanetakou, Athina Savva, Brigit Kersten, Aikaterini Pistiki, Frank L van de Veerdonk, Mihai G Netea, Jos W van der Meer, Evangelos J. Giamarellos-Bourboulis PLoS One 2015 Jun 19;10(6):e0130522 DOI: 10.1371/journal.pone.0130522View article 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. MGN was funded by
Completed study Official Study Title A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 2 sites in Greece Actual enrolment: 20 participants ClinicalTrials.gov Identifier: NCT01558375 EudraCT number: 2011-005145-12 National Organization for